Carbinoxamine Maleate Solution
NDC 64950-243
Product Information
Carbinoxamine Maleate is a ANDA-approved product labeled by Genus Lifesciences Inc.. Carbinoxamine is an antihistamine used to relieve symptoms of allergy, hay fever, and the common cold. It is supplied as a solution for oral administration. This product entry covers the primary NDC 64950-243 and 2 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
Code Structure Chart
Product Details
What is NDC 64950-243?
What are the uses of this product?
What are Active Ingredients of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- CARBINOXAMINE MALEATE (UNII: 02O55696WH)
- CARBINOXAMINE (UNII: 982A7M02H5) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- ANHYDROUS CITRIC ACID (UNII: XF417D3PSL)
- GLYCERIN (UNII: PDC6A3C0OX)
- METHYLPARABEN (UNII: A2I8C7HI9T)
- PROPYLENE GLYCOL (UNII: 6DC9Q167V3)
- PROPYLPARABEN (UNII: Z8IX2SC1OH)
- SODIUM CITRATE, UNSPECIFIED FORM (UNII: 1Q73Q2JULR)
- SORBITOL (UNII: 506T60A25R)
- WATER (UNII: 059QF0KO0R)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1010696 - carbinoxamine maleate 4 MG in 5 mL Oral Solution
- RxCUI: 1010696 - carbinoxamine maleate 0.8 MG/ML Oral Solution
- RxCUI: 1010696 - carbinoxamine maleate 0.8 MG/ML Oral Syrup
- RxCUI: 1010696 - carbinoxamine maleate 4 MG per 5 ML Oral Solution
- RxCUI: 1012904 - carbinoxamine maleate 4 MG Oral Tablet
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.